Rosiglitazone

This classification denotes a differentiation inducer and anti-diabetic agent with the molecular formula C18H19N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 05V02F2KDG, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)- but more generally known as rosiglitazone, which bears US NIH Compound Identifier 77999. European Medicines Agency schedules Rosiglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10388MIG. The term ROSIGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 2 1999, List 40) WHO schedules rosiglitazone in its Anatomical Therapeutic Chemical (ATC) Classification. ROSIGLITAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule rosiglitazone under HS 29341000 and SITC 51579. As of Q4 2014, ROSIGLITAZONE remains US FDA's Preferred Term for this commodity. Rosiglitazone bears US NLM identifiers UMLS ID C0289313 and NCI Concept Code C62076. SMILES: S1C(CC2CCC(OCCN(C3NCCCC3)C)CC2)C(=O)NC1=O.